Contribution of the interleukin-6-type cytokine Oncostatin M to the pathogenesis of non-alcoholic fatty liver disease

2015 ◽  
Vol 53 (09) ◽  
Author(s):  
HM Hermanns ◽  
C Schäfer ◽  
S Walter ◽  
D Dorbath ◽  
C Mais ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Interleukin 6 ◽  
Fatty Liver Disease ◽  
Oncostatin M ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals A study of Interleukin 6 as a predictive biomarker for development of nonalcholic steatohepatitis in patients with Nonalcholic fatty liver disease

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
K A Mohamed ◽  
E E Mohamed ◽  
D M Ahmed ◽  
M A Sayed ◽  
A R Hussien
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Interleukin 6 ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Simple Steatosis ◽  
Obesity And Diabetes ◽  
Significant Difference ◽  
And Control ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease worldwide, with a prevalence of 15%-30% in Western populations. Non-alcoholic fatty liver disease (NAFLD) has emerged as the most important cause of chronic liver disease related to the increase in incidence of obesity and diabetes mellitus type II in the population. Aim of the Work To predict nonalcholic steatohepatitis in patient with NAFLD through measurement of interleukin 6 to prevent progression of the disease into liver cirrhosis through early diagnosis. Patients and Methods This study was designed to be case control study; it was conducted on 70 patients selected from Internal Medicine and Hepatology outpatient clinics and inpatient wards at Ain Shams University Hospitals from (Jun/2017 to Jul 9/2018) and 20 healthy subjects as control group. Results NASH patients had more obesity (BMI 30) (83.3%) than both simple steatosis patients (57.5%) and control (55.0%). NASH patients had higher BMI as compared to simple steatosis patients and control (p value =0.01). The present study revealed that there is a statistically significant difference between groups according to IL6 (P > 0.001) as IL6 was positive in 70% of patients with NASH while in patients with simple steatosis and control was positive in 25%, 20% respectively. Conclusion NAFLD is a highly prevalent condition, shares many features of the metabolic syndrome (MetS), a highly atherogenic condition. Recommendations Large scale multi-centre studies are recommended to study the prevalence of NAFLD in Egypt. Further studies on the effect of presence of steatosis and increased risk of hepatocellular carcinoma.

scholarly journals PROTO-HORMONES LEVELS OF ADIPOSE TISSUE, INTERLEUKIN-6 AND INDICATORS OF DETOXIFYING FUNCTION OF THE LIVER IN PATIENTS WITH HYPERTENSION AND OBESITY COMBINED WITH NON-ALCOHOLIC FATTY LIVER DISEASE

2020 ◽  
pp. 3-6
Author(s):  
Olesia Bochar
Keyword(s):  
Adipose Tissue ◽  
Liver Disease ◽  
Arterial Hypertension ◽  
Fatty Liver ◽  
Interleukin 6 ◽  
Fatty Liver Disease ◽  
Left Ventricular ◽  
The Body ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

The research estimates the state of liver detoxifying function and analyzes the changes in the levels of leptin, adiponectin and interleukin-6 in patients with arterial hypertension in combination with obesity and non-alcoholic fatty liver disease. Aim. The aim of the study is to evaluate levels of proto-hormones adipose tissue, interleukin-6 and indicators of detoxifying function of the liver in patients with hypertension and obesity combined with non-alcoholic fatty liver disease (NAFLD). Materials and methods. The study involved patients with arterial hypertension combined with obesity and NAFLD. All patients underwent anthropometric, general clinical, laboratory (blood lipid profile) and instrumental diagnostics (electrocardiography, echocardiography, ultrasonography, 13C-metacetin breath test, ELISA (adiponectin, leptin, IL-6). The patients’ height and weight were measured, the body mass index was calculated according to standard formulas. Results. Patients with arterial hypertension combined with obesity and NAFLD at the stage of steatohepatitis showed an increase in the levels of leptin and IL-6 and a decrease in the level of adiponectin. This group also revealed a moderate decrease in liver detoxifying function, as indicated by the results of 13C- MBT due to a 46.7 % decrease in the metabolic rate and a decrease in cumulative doses of CUM40 by 40 % and CUM120 by 46.8 %, respectively. Conclusions. The elevated levels of leptin and IL-6 and lowered adiponectin levels can be used to determine the degree of activity of non-alcoholic steatohepatitis and predict the course of NAFLD in combination with hypertension and obesity. An increased level of leptin and IL-6 and a low level of adiponectin in patients with such a comorbid pathology lead to an increase in the left ventricular myocardial mass index and aggravate the course of arterial hypertension.

scholarly journals Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts

Cells ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. 28 ◽  
Author(s):  
Beatrice Foglia ◽  
Salvatore Sutti ◽  
Dario Pedicini ◽  
Stefania Cannito ◽  
Claudia Bocca ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Hypoxia Inducible Factor ◽  
Oncostatin M ◽  
Ros Generation ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Hepatic myofibroblasts (MFs) can originate from hepatic stellate cells, portal fibroblasts, or bone marrow-derived mesenchymal stem cells and can migrate towards the site of injury by aligning with nascent and established fibrotic septa in response to several mediators. Oncostatin M (OSM) is known to orchestrate hypoxia-modulated hepatic processes involving the hypoxia-inducible factor 1 (HIF-1). Methods. In vivo and in vitro experiments were performed to analyze the expression of OSM and OSM-receptor (OSMR) in three murine models of non-alcoholic-fatty liver disease (NAFLD) and -steatohepatitis (NASH) and in human NASH patients as well as the action of OSM on phenotypic responses of human MFs. Results: Hepatic OSM and OSMR levels were overexpressed in three murine NASH models and in NASH patients. OSM stimulates migration in human MFs by involving early intracellular ROS generation and activation of Ras/Erk, JNK1/2, PI3K/Akt as well as STAT1/STAT3 pathways and HIF-1α. OSM-dependent migration relies on a biphasic mechanism requiring early intracellular generation of reactive oxygen species (ROS) and late HIF1-dependent expression and release of VEGF. Conclusion: OSM is overexpressed in experimental and human progressive NAFLD and can act as a profibrogenic factor by directly stimulating migration of hepatic MFs.

scholarly journals The Association between Interleukin-6 and Mean Platelet Volume Levels in Central Obesity with or without Non-Alcoholic Fatty Liver Disease

2020 ◽  
Vol 21 (3) ◽  
pp. 193-198
Author(s):  
Linda Rotty ◽  
Nelly Tendean ◽  
Nancy Lestari ◽  
Randy Adiwinata
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Interleukin 6 ◽  
Mean Platelet Volume ◽  
Fatty Liver Disease ◽  
Central Obesity ◽  
Platelet Volume ◽  
Alcoholic Fatty Liver ◽  
Sample Group ◽  
Alcoholic Fatty Liver Disease

Background: Obesity had become a global problem today. Obesity is a significant risk factor of cardiovascular and other metabolic diseases such as non-alcoholic fatty liver disease (NAFLD). It remains unclear if the increased mean platelet volume (MPV) at the steatosis state is practicable as early detection of the occurrence of fatty liver in individuals with central obesity. This study aims to determine the association of interleukin-6 (IL-6) and MPV levels in central obesity with or without NAFLD.Method: This study was descriptive-analytic with a cross-sectional approach conducted in Prof. dr. R. D. Kandou Manado general hospital from May to July 2018. Consecutive sampling was performed based on inclusion criteria, then IL-6, MPV, and abdominal ultrasound examinations were performed.Results: This study included 40 samples of men with central obesity, 28 people (70%) among them were diagnosed with NAFLD. The Fisher exact test showed an association between NAFLD and an increase in IL-6 (p = 0.039), also between MPV and NAFLD (p=0.015). Pearson correlation test showed there was no significant correlation between IL-6 and MPV in the NAFLD sample group (p = 0.084; r -0.332) and in the non-NAFLD sample group (p = 0.564; r -0.186).Conclusion: Elevated MPV and IL-6 values may be used as marker for NAFLD presence among central obesity patients.

Sign in / Sign up

Export Citation Format

Share Document